FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

This study is testing whether a drug called fezolinetant can reduce hot flashes and other vasomotor symptoms (sudden feelings of heat, sweating, flushing) in women with hormone receptor-positive (HR+) breast cancer who are taking hormonal therapy like tamoxifen or aromatase inhibitors. **You may be eligible if...** - You are a woman between 40 and 65 years old with a BMI between 18 and 40 - You have been diagnosed with stage I-III HR+ invasive breast cancer - You have been on endocrine therapy (tamoxifen or an aromatase inhibitor) for at least 3 months and plan to continue for at least 12 more weeks - You are experiencing 7 or more moderate-to-severe hot flashes per day and want relief - You are postmenopausal or chemically menopausal (on GnRH agonist therapy) **You may NOT be eligible if...** - You have stage IV (metastatic) breast cancer - You are premenopausal and not on ovarian suppression therapy - You are not on endocrine therapy Talk to your doctor to see if this trial is right for you.